Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685590 · ClinicalTrials.gov registry record · Phase 2
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
A Phase 2 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT04685590: Active Phase 2 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, sponsored by Washington University School of Medicine.
NCT04685590 is a Phase 2 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 48 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04685590, a Phase 2 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Primary Outcome
Adverse Events (AEs) and SAEs will be collected at each in-person visit and at scheduled telephone visits from baseline to week 48. Incidence of SAEs between groups (treatment vs. placebo) will be reviewed by the Data Safety Monitoring Board (DSMB) for clinical significance.
Conditions Studied
Interventions
- OTHER Placebo Capsules
- DRUG Dasatinib + Quercetin
Study Locations (5)
Other
- Fundación ACE Clinical Site - Barcelona
- Hospital Clínic de Barcelona Site - Barcelona
- Sant Pau Clinical Site - Barcelona
- FISEVI Clinical Site - Seville
North Carolina
- Wake Forest Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What the registry record for NCT04685590 still lists
NCT04685590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo Capsules is the first listed.
NCT04685590 lists 5 locations in 2 states (Other, North Carolina).
Frequently Asked Questions
What is clinical trial NCT04685590 about?
NCT04685590 is a clinical study titled "Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study". The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
What is the current status of trial NCT04685590?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2021-12-22. Estimated completion is 2029-01.
What conditions does trial NCT04685590 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimer Disease, Early Onset.
What interventions are being tested in trial NCT04685590?
The interventions under investigation include: Placebo Capsules (OTHER), Dasatinib + Quercetin (DRUG).
Who is sponsoring clinical trial NCT04685590?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685590 being conducted?
This trial has 5 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04685590's enrollment target sits among peer trials
48 145th of 205 higher than 58 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
RECRUITING · Phase 2
-
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
RECRUITING · Phase 2
-
Rapamycin - Effects on Alzheimer's and Cognitive Health
RECRUITING · Phase 2
-
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI